title: Clinical practice guidelines on antiemetics in oncology.
abstract: The tolerability of chemotherapy has been significantly improved by the advent of effective drugs and protocols for the amelioration of chemotherapy-induced nausea and vomiting. Variables such as the timing of nausea and vomiting (acute, delayed or anticipatory) and the emetogenicity of the chemotherapy must be taken into account in developing guidelines for antiemetic prophylaxis and treatment. Although there are a number of 5-hydroxytryptamine antagonists available, the clinical differences between them are small. The use of drugs with a different mechanism of action, such as the recently introduced neurokinin-1 receptor antagonist aprepitant, may be a useful adjunct to 5-hydroxytryptamine-3 receptor antagonists or steroid prophylaxis. The addition of aprepitant to standard antiemetic regimens increases the proportion of complete responses to antiemetic therapy. For the use of highly emetogenic chemotherapy in oncology a combination of 5-hydroxytryptamine-3 receptor antagonist, dexamethasone and aprepitant is recommended in the acute phase, and dexamethasone plus aprepitant during the subsequent days (many patients do not have their symptoms controlled by 5-hydroxytryptamine-3 receptor antagonist and steroid alone). In either case, lorazepam can be added as required. For moderately emetogenic chemotherapy, a regimen of 5-hydroxytryptamine, dexamethasone and aprepitant is recommended in the acute phase, followed by aprepitant alone in the delayed phase. Alternatively, a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone can be used in the acute phase, followed by dexamethasone for prophylaxis in the delayed phase. For chemotherapy with a low emetogenicity, either dexamethasone, metoclopramide, prochlorperazine or triethyperazine alone is recommended. No prophylaxis is generally required during the delayed phase and indeed may not be necessary during the acute phase either.
authors.affiliation: H. Universitario Reina Sofía, Avda. Menendez Pidal, s/n, 14004 Córdoba, Spain. earandaa@seom.org
authors.forename: Enrique
authors.initials: E
authors.lastname: Aranda Aguilar
authors.forename: Manuel
authors.initials: M
authors.lastname: Constenla Figueiras
authors.forename: Hernán
authors.initials: H
authors.lastname: Cortes-Funes
authors.forename: Eduardo
authors.initials: E
authors.lastname: Diaz-Rubio García
authors.forename: Pere
authors.initials: P
authors.lastname: Gascon Vilaplana
authors.forename: Vicente
authors.initials: V
authors.lastname: Guillém
authors.forename: Salvador
authors.initials: S
authors.lastname: Martin-Algarra
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists